Long-term follow-up of severely symptomatic women with adenomyoma treated with combination therapy

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Objective: The aim of our study was to assess the long-term efficacy of conservative surgery combined with gonadotropin-releasing hormone agonist therapy for uterine adenomyoma. Materials and Methods: We carried out an uncontrolled descriptive study of 285 women who had symptomatic uterine adenomyoma. A total of 186 women with pathologically proven adenomyoma underwent ultramini-laparoscopic adenomyomectomy and a 6-month course of goserelin acetate treatment, and were evaluated semi-annually during a follow-up period of at least 3 years. Results: Patient scores for dysmenorrhea using a self-reported six-point verbal numeric rating scale significantly declined compared with the baseline assessment, from 3.84 ± 0.65 to 0.33 ± 0.57, 0.52 ± 0.86, and 0.88 ± 1.29 at the end of the 1-, 2-, and 3-year follow-up visits, respectively (p <0.001). Similar reductions were observed for analgesic usage scores. Menorrhagia scores significantly decreased compared with the baseline assessment, from 3.45 ± 1.46 to 0.42 ± 0.59, 0.65 ± 0.83, and 1.1 ± 1.34 at the end of the 1-, 2-, and 3-year follow-up visits, respectively (p <0.001). Conclusion: Combination therapy for adenomyoma provides an effective treatment option for long-term symptom control and uterine preservation in severely symptomatic women for whom previous long-term drug therapy has failed or proven to be intolerable.

Original languageEnglish
Pages (from-to)85-89
Number of pages5
JournalTaiwanese Journal of Obstetrics and Gynecology
Volume52
Issue number1
DOIs
Publication statusPublished - Mar 2013

Fingerprint

Adenomyoma
Goserelin
Menorrhagia
Dysmenorrhea
Therapeutics
Gonadotropin-Releasing Hormone
Analgesics
Drug Therapy

Keywords

  • Adenomyoma
  • Conservative surgery
  • Gonadotropin-releasing hormone agonist

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

@article{e5e174b1a02145c3b349586819246628,
title = "Long-term follow-up of severely symptomatic women with adenomyoma treated with combination therapy",
abstract = "Objective: The aim of our study was to assess the long-term efficacy of conservative surgery combined with gonadotropin-releasing hormone agonist therapy for uterine adenomyoma. Materials and Methods: We carried out an uncontrolled descriptive study of 285 women who had symptomatic uterine adenomyoma. A total of 186 women with pathologically proven adenomyoma underwent ultramini-laparoscopic adenomyomectomy and a 6-month course of goserelin acetate treatment, and were evaluated semi-annually during a follow-up period of at least 3 years. Results: Patient scores for dysmenorrhea using a self-reported six-point verbal numeric rating scale significantly declined compared with the baseline assessment, from 3.84 ± 0.65 to 0.33 ± 0.57, 0.52 ± 0.86, and 0.88 ± 1.29 at the end of the 1-, 2-, and 3-year follow-up visits, respectively (p <0.001). Similar reductions were observed for analgesic usage scores. Menorrhagia scores significantly decreased compared with the baseline assessment, from 3.45 ± 1.46 to 0.42 ± 0.59, 0.65 ± 0.83, and 1.1 ± 1.34 at the end of the 1-, 2-, and 3-year follow-up visits, respectively (p <0.001). Conclusion: Combination therapy for adenomyoma provides an effective treatment option for long-term symptom control and uterine preservation in severely symptomatic women for whom previous long-term drug therapy has failed or proven to be intolerable.",
keywords = "Adenomyoma, Conservative surgery, Gonadotropin-releasing hormone agonist",
author = "Wei-Min Liu and Chen, {Ching Hui} and Chiu, {Li Hsuan} and Chii-Ruey Tzeng",
year = "2013",
month = "3",
doi = "10.1016/j.tjog.2012.12.002",
language = "English",
volume = "52",
pages = "85--89",
journal = "Taiwanese Journal of Obstetrics and Gynecology",
issn = "1028-4559",
publisher = "臺灣婦產科醫學會",
number = "1",

}

TY - JOUR

T1 - Long-term follow-up of severely symptomatic women with adenomyoma treated with combination therapy

AU - Liu, Wei-Min

AU - Chen, Ching Hui

AU - Chiu, Li Hsuan

AU - Tzeng, Chii-Ruey

PY - 2013/3

Y1 - 2013/3

N2 - Objective: The aim of our study was to assess the long-term efficacy of conservative surgery combined with gonadotropin-releasing hormone agonist therapy for uterine adenomyoma. Materials and Methods: We carried out an uncontrolled descriptive study of 285 women who had symptomatic uterine adenomyoma. A total of 186 women with pathologically proven adenomyoma underwent ultramini-laparoscopic adenomyomectomy and a 6-month course of goserelin acetate treatment, and were evaluated semi-annually during a follow-up period of at least 3 years. Results: Patient scores for dysmenorrhea using a self-reported six-point verbal numeric rating scale significantly declined compared with the baseline assessment, from 3.84 ± 0.65 to 0.33 ± 0.57, 0.52 ± 0.86, and 0.88 ± 1.29 at the end of the 1-, 2-, and 3-year follow-up visits, respectively (p <0.001). Similar reductions were observed for analgesic usage scores. Menorrhagia scores significantly decreased compared with the baseline assessment, from 3.45 ± 1.46 to 0.42 ± 0.59, 0.65 ± 0.83, and 1.1 ± 1.34 at the end of the 1-, 2-, and 3-year follow-up visits, respectively (p <0.001). Conclusion: Combination therapy for adenomyoma provides an effective treatment option for long-term symptom control and uterine preservation in severely symptomatic women for whom previous long-term drug therapy has failed or proven to be intolerable.

AB - Objective: The aim of our study was to assess the long-term efficacy of conservative surgery combined with gonadotropin-releasing hormone agonist therapy for uterine adenomyoma. Materials and Methods: We carried out an uncontrolled descriptive study of 285 women who had symptomatic uterine adenomyoma. A total of 186 women with pathologically proven adenomyoma underwent ultramini-laparoscopic adenomyomectomy and a 6-month course of goserelin acetate treatment, and were evaluated semi-annually during a follow-up period of at least 3 years. Results: Patient scores for dysmenorrhea using a self-reported six-point verbal numeric rating scale significantly declined compared with the baseline assessment, from 3.84 ± 0.65 to 0.33 ± 0.57, 0.52 ± 0.86, and 0.88 ± 1.29 at the end of the 1-, 2-, and 3-year follow-up visits, respectively (p <0.001). Similar reductions were observed for analgesic usage scores. Menorrhagia scores significantly decreased compared with the baseline assessment, from 3.45 ± 1.46 to 0.42 ± 0.59, 0.65 ± 0.83, and 1.1 ± 1.34 at the end of the 1-, 2-, and 3-year follow-up visits, respectively (p <0.001). Conclusion: Combination therapy for adenomyoma provides an effective treatment option for long-term symptom control and uterine preservation in severely symptomatic women for whom previous long-term drug therapy has failed or proven to be intolerable.

KW - Adenomyoma

KW - Conservative surgery

KW - Gonadotropin-releasing hormone agonist

UR - http://www.scopus.com/inward/record.url?scp=84878017989&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878017989&partnerID=8YFLogxK

U2 - 10.1016/j.tjog.2012.12.002

DO - 10.1016/j.tjog.2012.12.002

M3 - Article

C2 - 23548225

AN - SCOPUS:84878017989

VL - 52

SP - 85

EP - 89

JO - Taiwanese Journal of Obstetrics and Gynecology

JF - Taiwanese Journal of Obstetrics and Gynecology

SN - 1028-4559

IS - 1

ER -